224 related articles for article (PubMed ID: 38467779)
1. TYK2: an emerging therapeutic target in rheumatic disease.
Morand E; Merola JF; Tanaka Y; Gladman D; Fleischmann R
Nat Rev Rheumatol; 2024 Apr; 20(4):232-240. PubMed ID: 38467779
[TBL] [Abstract][Full Text] [Related]
2. English version of Japanese guidance for the use of oral Janus kinase inhibitors (JAK1 and TYK2 inhibitors) in the treatments of psoriasis.
Saeki H; Mabuchi T; Asahina A; Abe M; Igarashi A; Imafuku S; Okubo Y; Komine M; Takahashi K; Torii H; Morita A; Yotsuyanagi H; Watanabe A; Ohtsuki M;
J Dermatol; 2023 May; 50(5):e138-e150. PubMed ID: 37132187
[TBL] [Abstract][Full Text] [Related]
3. Clinical Implications of Targeting the JAK-STAT Pathway in Psoriatic Disease: Emphasis on the TYK2 Pathway.
Loo WJ; Turchin I; Prajapati VH; Gooderham MJ; Grewal P; Hong CH; Sauder M; Vender RB; Maari C; Papp KA
J Cutan Med Surg; 2023; 27(1_suppl):3S-24S. PubMed ID: 36519621
[TBL] [Abstract][Full Text] [Related]
4. A novel highly selective allosteric inhibitor of tyrosine kinase 2 (TYK2) can block inflammation- and autoimmune-related pathways.
Chen CX; Zhang W; Qu S; Xia F; Zhu Y; Chen B
Cell Commun Signal; 2023 Oct; 21(1):287. PubMed ID: 37845748
[TBL] [Abstract][Full Text] [Related]
5. Deucravacitinib is an allosteric TYK2 protein kinase inhibitor FDA-approved for the treatment of psoriasis.
Roskoski R
Pharmacol Res; 2023 Mar; 189():106642. PubMed ID: 36754102
[TBL] [Abstract][Full Text] [Related]
6. JAK Inhibitors for Treatment of Psoriasis: Focus on Selective TYK2 Inhibitors.
Nogueira M; Puig L; Torres T
Drugs; 2020 Mar; 80(4):341-352. PubMed ID: 32020553
[TBL] [Abstract][Full Text] [Related]
7. Janus-kinase inhibitors in dermatology: A review of their use in psoriasis, vitiligo, systemic lupus erythematosus, hidradenitis suppurativa, dermatomyositis, lichen planus, lichen planopilaris, sarcoidosis and graft-versus-host disease.
Huang MY; Armstrong AW
Indian J Dermatol Venereol Leprol; 2023 [SEASON]; 90(1):30-40. PubMed ID: 38031699
[TBL] [Abstract][Full Text] [Related]
8. Tyrosine kinase 2 and Janus kinase‒signal transducer and activator of transcription signaling and inhibition in plaque psoriasis.
Krueger JG; McInnes IB; Blauvelt A
J Am Acad Dermatol; 2022 Jan; 86(1):148-157. PubMed ID: 34224773
[TBL] [Abstract][Full Text] [Related]
9. TYK2 as a therapeutic target in the treatment of autoimmune and inflammatory diseases.
Gonciarz M; Pawlak-Buś K; Leszczyński P; Owczarek W
Immunotherapy; 2021 Sep; 13(13):1135-1150. PubMed ID: 34235974
[TBL] [Abstract][Full Text] [Related]
10. Allosteric TYK2 inhibition: redefining autoimmune disease therapy beyond JAK1-3 inhibitors.
Jensen LT; Attfield KE; Feldmann M; Fugger L
EBioMedicine; 2023 Nov; 97():104840. PubMed ID: 37863021
[TBL] [Abstract][Full Text] [Related]
11. Selective Tyk2 inhibitors as potential therapeutic agents: a patent review (2015-2018).
He X; Chen X; Zhang H; Xie T; Ye XY
Expert Opin Ther Pat; 2019 Feb; 29(2):137-149. PubMed ID: 30621465
[TBL] [Abstract][Full Text] [Related]
12. Selective Tyrosine Kinase 2 Inhibition for Treatment of Inflammatory Bowel Disease: New Hope on the Rise.
Danese S; Peyrin-Biroulet L
Inflamm Bowel Dis; 2021 Nov; 27(12):2023-2030. PubMed ID: 34089259
[TBL] [Abstract][Full Text] [Related]
13. Discovery of Tyrosine Kinase 2 (TYK2) Inhibitor (PF-06826647) for the Treatment of Autoimmune Diseases.
Gerstenberger BS; Ambler C; Arnold EP; Banker ME; Brown MF; Clark JD; Dermenci A; Dowty ME; Fensome A; Fish S; Hayward MM; Hegen M; Hollingshead BD; Knafels JD; Lin DW; Lin TH; Owen DR; Saiah E; Sharma R; Vajdos FF; Xing L; Yang X; Yang X; Wright SW
J Med Chem; 2020 Nov; 63(22):13561-13577. PubMed ID: 32787094
[TBL] [Abstract][Full Text] [Related]
14. Selectivity Profile of the Tyrosine Kinase 2 Inhibitor Deucravacitinib Compared with Janus Kinase 1/2/3 Inhibitors.
Chimalakonda A; Burke J; Cheng L; Catlett I; Tagen M; Zhao Q; Patel A; Shen J; Girgis IG; Banerjee S; Throup J
Dermatol Ther (Heidelb); 2021 Oct; 11(5):1763-1776. PubMed ID: 34471993
[TBL] [Abstract][Full Text] [Related]
15. Novel Small Molecule Tyrosine Kinase 2 Pseudokinase Ligands Block Cytokine-Induced TYK2-Mediated Signaling Pathways.
Zhou Y; Li X; Shen R; Wang X; Zhang F; Liu S; Li D; Liu J; Li P; Yan Y; Dong P; Zhang Z; Wu H; Zhuang L; Chowdhury R; Miller M; Issa M; Mao Y; Chen H; Feng J; Li J; Bai C; He F; Tao W
Front Immunol; 2022; 13():884399. PubMed ID: 35693820
[TBL] [Abstract][Full Text] [Related]
16. Selective TYK2 inhibitors as potential therapeutic agents: a patent review (2019-2021).
Gonzalez Lopez de Turiso F; Guckian K
Expert Opin Ther Pat; 2022 Apr; 32(4):365-379. PubMed ID: 35001782
[TBL] [Abstract][Full Text] [Related]
17. Targeting the Tyrosine Kinase 2 (TYK2) Pseudokinase Domain: Discovery of the Selective TYK2 Inhibitor ABBV-712.
Breinlinger E; Van Epps S; Friedman M; Argiriadi M; Chien E; Chhor G; Cowart M; Dunstan T; Graff C; Hardee D; Herold JM; Little A; McCarthy R; Parmentier J; Perham M; Qiu W; Schrimpf M; Vargo T; Webster MP; Wu F; Bennett D; Edmunds J
J Med Chem; 2023 Oct; 66(20):14335-14356. PubMed ID: 37823891
[TBL] [Abstract][Full Text] [Related]
18. Inhibition of TYK2 and JAK1 ameliorates imiquimod-induced psoriasis-like dermatitis by inhibiting IL-22 and the IL-23/IL-17 axis.
Works MG; Yin F; Yin CC; Yiu Y; Shew K; Tran TT; Dunlap N; Lam J; Mitchell T; Reader J; Stein PL; D'Andrea A
J Immunol; 2014 Oct; 193(7):3278-87. PubMed ID: 25156366
[TBL] [Abstract][Full Text] [Related]
19. Selective JAK1 inhibitor and selective Tyk2 inhibitor patents.
Norman P
Expert Opin Ther Pat; 2012 Oct; 22(10):1233-49. PubMed ID: 22971156
[TBL] [Abstract][Full Text] [Related]
20. Potent and Selective Knockdown of Tyrosine Kinase 2 by Antisense Oligonucleotides.
Tran NV; Nguyen LTA; Lim KW; Phan AT
Immunohorizons; 2021 Feb; 5(2):70-80. PubMed ID: 33542028
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
